NO20020319L - Oftalmisk sammensetning - Google Patents

Oftalmisk sammensetning

Info

Publication number
NO20020319L
NO20020319L NO20020319A NO20020319A NO20020319L NO 20020319 L NO20020319 L NO 20020319L NO 20020319 A NO20020319 A NO 20020319A NO 20020319 A NO20020319 A NO 20020319A NO 20020319 L NO20020319 L NO 20020319L
Authority
NO
Norway
Prior art keywords
ophthalmic composition
ophthalmic
composition
Prior art date
Application number
NO20020319A
Other languages
English (en)
Other versions
NO20020319D0 (no
NO331228B1 (no
Inventor
Marcia Johanna Adam
Andrea Fetz
Gyoergy Lajos Kis
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20020319D0 publication Critical patent/NO20020319D0/no
Publication of NO20020319L publication Critical patent/NO20020319L/no
Publication of NO331228B1 publication Critical patent/NO331228B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20020319A 1999-07-23 2002-01-21 Anvendelse av en sammensetning som omfatter et ketotifensalt NO331228B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99114508 1999-07-23
PCT/EP2000/007030 WO2001007049A2 (en) 1999-07-23 2000-07-21 Ophthalmic composition comprising ketotifen

Publications (3)

Publication Number Publication Date
NO20020319D0 NO20020319D0 (no) 2002-01-21
NO20020319L true NO20020319L (no) 2002-01-21
NO331228B1 NO331228B1 (no) 2011-11-07

Family

ID=8238654

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020319A NO331228B1 (no) 1999-07-23 2002-01-21 Anvendelse av en sammensetning som omfatter et ketotifensalt

Country Status (20)

Country Link
US (2) US6777429B1 (no)
EP (1) EP1198223A2 (no)
JP (1) JP2003505419A (no)
KR (1) KR20020012261A (no)
CN (1) CN1358086A (no)
BR (2) BR0012696A (no)
CA (1) CA2377024A1 (no)
CZ (1) CZ300614B6 (no)
EE (1) EE05439B1 (no)
HK (1) HK1046631A1 (no)
HU (1) HU230738B1 (no)
IL (1) IL146973A0 (no)
MX (1) MXPA02000849A (no)
NO (1) NO331228B1 (no)
NZ (1) NZ516108A (no)
PL (1) PL202496B1 (no)
RU (1) RU2248789C2 (no)
UA (1) UA74788C2 (no)
WO (1) WO2001007049A2 (no)
ZA (1) ZA200200425B (no)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR034372A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
AR034371A1 (es) * 2001-06-08 2004-02-18 Novartis Ag Composiciones farmaceuticas
WO2002100436A2 (en) * 2001-06-08 2002-12-19 Novartis Ag Ophthalmic once-a-day composition
KR20050092429A (ko) * 2003-01-22 2005-09-21 니찌방 가부시기가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
WO2006047418A1 (en) * 2004-10-25 2006-05-04 Alimera Sciences, Inc. Ophthalmic compositions and methods of using the same
US20060089384A1 (en) * 2004-10-25 2006-04-27 Minno George E Ophthalmic compositions and methods of using the same
US20070208058A1 (en) * 2004-10-25 2007-09-06 Bryant Roy W Stable Pharmaceutical Compositions and Methods of Making and Using Same
US20070048389A1 (en) * 2005-08-26 2007-03-01 Fu-Pao Tsao Stabilized and preserved ketotifen ophthalmic compositions
US20070077302A1 (en) * 2005-09-30 2007-04-05 Azaam Alli Methods for stabilizing ophthalmic compositions
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
US8445437B2 (en) * 2006-07-27 2013-05-21 The Brigham And Women's Hospital, Inc. Treatment and prevention of cardiovascular disease using mast cell stabilizers
BRPI0718374A2 (pt) * 2006-09-29 2013-06-25 Johnson & Johnson Vision Care mÉtodos e dispositivos oftÁlmicos usados no tratamento de alergias oculares
US20100166804A1 (en) * 2007-05-23 2010-07-01 Dennis Penn Methods
JP5460600B2 (ja) 2007-09-28 2014-04-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 肥満症治療における肥満細胞安定化薬
WO2009142772A2 (en) * 2008-05-23 2009-11-26 Mastcell Pharmaceuticals, Inc. Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
WO2010107525A1 (en) * 2009-03-17 2010-09-23 Aciex Therapeutics, Inc. Ophthalmic formulations of ketotifen and methods of use
RU2549472C1 (ru) * 2013-12-26 2015-04-27 Илья Александрович Марков Фармацевтическая композиция в форме капель для профилактики и лечения аллергических заболеваний глаз
PT3384049T (pt) 2015-12-03 2023-08-18 Regeneron Pharma Método de associação de variantes genéticas com um resultado clínico em doentes que sofrem de degeneração macular relacionada à idade tratados com anti-vegf
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111450051B (zh) * 2020-04-21 2022-03-18 武汉贝参药业股份有限公司 一种富马酸酮替芬口服溶液的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62277323A (ja) 1986-02-19 1987-12-02 Sankyo Co Ltd フマル酸ケトチフエン含有点眼液の製法
RU2003350C1 (ru) * 1991-03-01 1993-11-30 Институт иммунологии Способ лечени глюкокортикостероидзависимых атопических заболеваний
RU2007117C1 (ru) * 1992-03-20 1994-02-15 Юлия Михайловна Залесская Способ индивидуального подбора веществ для коррекции нарушений в организме
ES2141775T3 (es) * 1993-04-16 2000-04-01 Wakamoto Pharma Co Ltd Composicion medicinal a base de agua termicamente gelificante reversible.
JPH07324034A (ja) * 1994-05-30 1995-12-12 Toa Yakuhin Kk フマル酸ケトチフェン含有の点眼剤
JPH11189533A (ja) * 1997-12-25 1999-07-13 Taisho Pharmaceut Co Ltd 点眼薬
EP0938896A1 (en) 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent

Also Published As

Publication number Publication date
PL202496B1 (pl) 2009-06-30
NO20020319D0 (no) 2002-01-21
WO2001007049A3 (en) 2001-03-29
PL352382A1 (en) 2003-08-25
EE200200040A (et) 2003-04-15
BRPI0017528B8 (pt) 2021-05-25
RU2248789C2 (ru) 2005-03-27
KR20020012261A (ko) 2002-02-15
UA74788C2 (en) 2006-02-15
HK1046631A1 (zh) 2003-01-24
MXPA02000849A (es) 2002-07-30
NZ516108A (en) 2004-04-30
BRPI0017528A2 (pt) 2010-01-19
CZ2002243A3 (cs) 2002-04-17
EP1198223A2 (en) 2002-04-24
US6777429B1 (en) 2004-08-17
IL146973A0 (en) 2002-08-14
US6774137B2 (en) 2004-08-10
HUP0202243A3 (en) 2006-03-28
CZ300614B6 (cs) 2009-07-01
NO331228B1 (no) 2011-11-07
BRPI0017528B1 (pt) 2017-06-13
ZA200200425B (en) 2002-10-30
US20020183359A1 (en) 2002-12-05
JP2003505419A (ja) 2003-02-12
WO2001007049A2 (en) 2001-02-01
CA2377024A1 (en) 2001-02-01
HU230738B1 (hu) 2018-01-29
EE05439B1 (et) 2011-08-15
BR0012696A (pt) 2002-04-09
CN1358086A (zh) 2002-07-10
HUP0202243A2 (hu) 2002-12-28

Similar Documents

Publication Publication Date Title
IS6120A (is) Lyfjablanda
NO20021116D0 (no) Ny sammensetning
ID26056A (id) Popok sekali pakai
DE60013863D1 (de) Photochromische indeno-kondensierte naphtopyrane
ID26389A (id) Popok sekali pakai
AR023440A1 (es) Composiciones antitranspirantes
NO20021115L (no) Ny sammensetning
ID29785A (id) Komposisi-komposisi sampo
NO20020319D0 (no) Oftalmisk sammensetning
ATE257691T1 (de) Schweisshemmende zusammensetzungen
DE69943245D1 (de) Gaserzeugende zusammensetzung
DE60009363D1 (de) Kautschukzusammensetzung
ID25571A (id) Popok sekali pakai
DK1218304T3 (da) Glasfibersammensætning
ID24782A (id) Popok sekali pakai
NO20003786D0 (no) Oftalmisk sammensetning
DE10081095T1 (de) Kautschukzusammensetzung
ITMO990105A0 (it) Occhiali
FI19992609A7 (fi) Uusi koostumus
DE60020682D1 (de) Resorcinenthaltende zusammensetzung
ID27329A (id) Komposisi penghambat
DE10084920T1 (de) Glaszusammensetzung
NO20022845D0 (no) Limsammensetning
NO20023162D0 (no) Organometallkatalysatorblandinger
ID30320A (id) Komposisi-komposisi berpigmen

Legal Events

Date Code Title Description
MK1K Patent expired